MedTrace Logo

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19

NCT03497533 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-09-06

No results posted yet for this study

Summary

This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).

Conditions

  • Non-hodgkin Lymphoma,B Cell

Interventions

BIOLOGICAL

TriCAR-T-CD19

A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg

Sponsors & Collaborators

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • Timmune Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Ming Zhou · Hunan Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-03
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497533 on ClinicalTrials.gov